Planet Green responds to unusual NYSE trading activity
Planet Green Holdings Corp. notified the NYSE of unusual market activity on October 19, 2026, stating it is not aware of new material information to explain the surge. The company …
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Planet Green Holdings Corp. notified the NYSE of unusual market activity on October 19, 2026, stating it is not aware of new material information to explain the surge. The company …
The FDA approved the country's first generic version of Climara Pro, a once-weekly transdermal hormone therapy patch for women with intact uteruses. This includes a fixed combinati…
Lion Copper has started trading on the Nasdaq at the ticker symbol 'LCU'. This uplisting enhances visibility and broadens access to U.S. investors as the company advances its flags…
The FDA released final guidance establishing a framework for developing, distributing, and labeling prescription drug apps. The final rule clarifies regulatory oversight by classif…
Xterax Corp II adopted new amended and restated charter and articles effective Oct 19, 2026. The filing provides updated details regarding the company structure.
The company is displaying data from its study of pelareorep in colorectal cancer at the annual ESMO conference. Positive results from a previous trial support accelerated approval …
DataMeds AI, Inc. has received confirmation from Nasdaq that it has regained compliance with the stock's critical minimum equity Listing Rule after passing the $2.5 million thresho…
Beazer Homes USA Inc filed an amended restated certificate of incorporation with the SEC, reflecting procedural updates to the company's formation documents.
Freenome today announced the commercial launch of its SimpleScreen Lung blood test for eligible adults, following earlier FDA approval, enabling doctors to screen for lung and colo…
Microbot Medical received several new patent approvals across the U.S., Japan, China, and Canada, bringing its total intellectual property portfolio to 93 patents and applications.
Quoin Pharmaceuticals reported the successful compassionate-use treatment of a pediatric patient using QRX003, which resulted in dramatic skin improvements and significant symptom …
City Therapeutics, Inc. filed an amended and restated certificate of incorporation with the Delaware Secretary of State, revising its authorized capital stock structure. This SEC f…
La Rosa Holdings Corp. has filed to implement a 1-for-25 reverse split of its common stock to regain compliance with Nasdaq filing requirements. This strategic move is intended to …
Medalist Diversified, Inc. filed a Certificate of Correction to amend its Articles of Amendment to the charter with the State Department of Assessments and Taxation, which previous…
Accelerated approval of dostarlimab-gxly (Jemperli) allows some patients with locally advanced rectal cancer to avoid chemotherapy and surgery.
iBio's Board proposed an amendment to its 2023 Omnibus Incentive Plan to modify the 'evergreen' provision that automatically increases shares available for issuance, subject to sto…
SpyGlass Pharma announced positive 4-year safety and efficacy results from a first-in-human trial of its BIM-IOL System, showing significant intraocular pressure reduction and drop…
BioCardia announced FDA acceptance of its revised submission for the Helix catheter, marking the start of substantive review expected this quarter. The approval paves the way for e…
Veradermics reported positive Phase 3 trial results for its oral hair growth drug, VDPHL01, potentially becoming the first FDA-approved non-hormonal pill for male pattern baldness.
ArriVent BioPharma announced positive preclinical and clinical results from the FURTHER Phase 1b trial of firmonertinib for advanced EGFR PACC-mutant NSCLC. The company believes th…